Page last updated: 2024-08-23

cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous

cabergoline has been researched along with Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous in 62 studies

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (19.35)29.6817
2010's39 (62.90)24.3611
2020's11 (17.74)2.80

Authors

AuthorsStudies
Shi, H; Wu, D; Yu, T; Yu, Y; Zhai, J1
Karakus, C; Ozyurt, R; Turktekin, N1
Dahan, MH; Mills, G1
Bakırcı, Ş; Bulanık, M; Devrim, T; Gözüyukarı, H; Sağsöz, N; Şahin, Y1
Gulsen Coban, P; Haltas, H; Inal, HA; Timur, H; Yilmaz, N; Yilmaz, S1
Atabay, F; Ateş, Ç; Dilbaz, B; Ergani, SY1
Baba, K; Hayashi, N; Huang, H; Ichinose, S; Itaya, Y; Matsunaga, S; Narita, T; Ono, Y; Saitoh, M; Samejima, K; Seki, H; Takai, Y1
Erbas, O; Hortu, I; Karadadas, E; Ozceltik, G; Tavmergen Goker, EN; Tavmergen, E; Yigitturk, G1
Hart, RJ; Mourad, SM; Tang, H; Wang, A; Zhai, SD1
Hubka, Petr; Lincová, Marcela; Sehnal, Borek; Višňová, Hana; Zikán, Michal1
Elshaer, HS; Farouk, M; Fouda, UM; Hanafy, A; Mehrem, WM; Nabil, H; Youssef, GG; Youssef, MA1
Abdelsalam, EA; Elmahdy, M; Maghraby, HA1
Basly, M; Chibani, M; Haj Hassine, A; Jellad, S; Mrabet, A; Rachdi, R1
Amso, NN; D'Angelo, A; Hassan, R1
Bassiouny, YA; Bayoumi, YA; Dakhly, DMR; Gouda, HM; Hassan, AA; Salaheldin, NM1
Čehić, E; Franulić, D; Grgić, F; Kasum, M; Lila, A; Orešković, S; Vujić, G1
Hefzy, E; Seyam, E1
Celik, H; Celik, S; Hatirnaz, ES; Hatirnaz, S; Soyer-Calıskan, C; Tosun, M1
Atilgan, R; Başpınar, M; Ilhan, N; Pala, Ş; Yavuzkır, Ş; Yılmaz, M1
Çilgin, H1
El Maghraby, HA; El-Gezary, D; Gaafar, S1
Balayla, J; Dahan, MH; Shrem, G; Son, WY; Steiner, N; Tannus, S; Volodarsky-Perel, A1
Chen, HJ; Hsieh, BC; Huang, LW; Huang, MZ; Hwang, JL; Lin, YH; Seow, KM; Tzeng, CR1
Bai, CH; Chen, HJ; Hsieh, BC; Huang, LW; Hwang, JL; Lin, YH; Seow, KM; Tzeng, CR1
Bozdag, G; Esinler, I; Karakocsokmensuer, L1
Cinar, O; Dilbaz, S; Duraker, R; Guvendag Guven, ES; Mentese, A; Ozdegirmenci, O1
Deveer, R; Engin-Ustun, Y; Moraloglu, O; Timur, H; Ustun, Y; Yılmaz, N; Yılmaz, S1
Andrés, M; Expósito, A; Matorras, R; Mendoza, R; Pijoan, JI; Prieto, B1
Leitao, VM; Martins, WP; Moroni, RM; Nastri, CO; Seko, LM1
Beketić-Orešković, L; Ježek, D; Kasum, M; Orešković, S; Pekez, M; Stanić, P; Vrčić, H1
Angelova, M; Kacarova, P; Kozovski, G1
Akdogan, A; Akman, L; Aktug, H; Erbas, O; Goker, EN; Sahin, G; Taskiran, D; Tavmergen, E1
Adali, E; Balcioğlu, E; Erken, G; Hismiogulları, AA; Taskin, MI; Topcu, O; Yay, A1
Akan, Z; Cengiz, H; Eskicioğlu, F; Sahin, N; Sivrikoz, ON; Turan, GA; Vatansever, S; Yeşil, H; Yilmaz, O; Zafer, A1
Apaydın, N; Cengiz, H; Eskicioğlu, F; Genç, M; Şahin, N; Sivrikoz, ON; Töz, E; Turan, GA1
Cengiz, H; Eskicioğlu, F; Genc, M; Gur, EB; Kasap, E; Sivrikoz, ON; Turan, GA; Yılmaz, O1
Elsetohy, KA; Elshaer, HS; Fouda, UM; Hammad, BE; Sayed, AM; Shaban, MM; Youssef, MA1
El Tokhy, O; El-Toukhy, T; Kopeika, J1
Hart, RJ; Mourad, S; Tang, H; Zhai, SD1
Brown, J; Farquhar, C; Mourad, S1
Abdelmassih, R; Abdelmassih, S; Abdelmassih, V; Carizza, C; Jine, LT; Nagy, P; Ravizzini, P; Salgueiro, L; Salgueiro, PT1
Garcia-Velasco, JA1
Ata, B; Orhaner, S; Seyhan, A; Urman, B1
Amols, MH; Coddington, CC; Hudson, SBA; Rollene, NL1
Hwang, JL; Lin, YH; Seow, KM1
Arioz, DT; Dilek, H; Koken, T; Saylan, A; Saylan, F; Yilmazer, M1
Bourdel, N; Delabaere, A; Jardon, K; Pouly, JL; Tran, X1
Alcázar, JL; Monedero, P; Nagore Setién, D1
Delgado-Rosas, F; Ferrero, H; Gaytan, F; Gaytan, M; Gómez, R; Morales, C; Pellicer, A; Simón, C; Zimmermann, RC1
Arabipoor, A; Aziminekoo, E; Bahmanabadi, A; Chehrazi, M; Hafezi, M; Tehraninejad, ES1
Hart, RJ; Hu, Y; Hunter, T; Sheng, X; Tang, H; Zhai, SD1
Aleyasin, A; Bahmaee, F; Hosseini, MA; Mahdavi, A; Safdarian, L1
Shaltout, A; Shohyab, A; Youssef, MA1
Creatsas, G; Kalampokas, E; Kalampokas, T1
Adamo, V; Manno, M; Marchesan, E; Tomei, F2
Alonso-Muriel, I; Gomez, R; Gonzalez-Izquierdo, M; Novella-Maestre, E; Pellicer, A; Remohi, J; Sanchez-Criado, J; Simon, C; Zimmermann, RC1
Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH1
Alvarez, C; Fernández-Sánchez, M; Gómez, R; Martí-Bonmatí, L; Novella-Maestre, E; Pellicer, A; Sanz, R; Simón, C1
Aboulghar, MA1
Alonso-Muriel, I; Alvarez, C; Bellver, J; Crespo, J; García, G; Pellicer, A; Simón, C1
De Santis, L; Doldi, N; Ferrari, A; Marelli, G; Marsiglio, E; Papaleo, E; Rofena, S1

Reviews

12 review(s) available for cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous

ArticleYear
Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Cabergoline; Female; Humans; Network Meta-Analysis; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic

2022
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    The Cochrane database of systematic reviews, 2021, 04-14, Volume: 4

    Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Placebos; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic

2021
Current possibilities in the prevention and therapy of ovarian hyperstimulation syndrome.
    Ceska gynekologie, 2021, Volume: 86, Issue:2

    Topics: Cabergoline; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Polycystic Ovary Syndrome

2021
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    The Cochrane database of systematic reviews, 2017, 05-23, Volume: 5

    Topics: Abortion, Spontaneous; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Pregnancy, Multiple; Randomized Controlled Trials as Topic; Withholding Treatment

2017
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome
    Acta clinica Croatica, 2017, Volume: 56, Issue:1

    Topics: Aminoquinolines; Bromocriptine; Buserelin; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Progestins; Triptorelin Pamoate

2017
Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
    Fertility and sterility, 2014, Volume: 101, Issue:3

    Topics: Cabergoline; Ergolines; Female; Humans; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted

2014
Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014, Volume: 30, Issue:12

    Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction

2014
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
    The Cochrane database of systematic reviews, 2016, 11-30, Volume: 11

    Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted

2016
Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.
    The Cochrane database of systematic reviews, 2017, 01-23, Volume: 1

    Topics: Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Metformin; Ovarian Hyperstimulation Syndrome; Pregnancy; Progesterone; Reproductive Techniques, Assisted; Review Literature as Topic

2017
How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists.
    Reproductive biomedicine online, 2009, Volume: 18 Suppl 2

    Topics: Cabergoline; Clinical Protocols; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Randomized Controlled Trials as Topic

2009
Cabergoline for preventing ovarian hyperstimulation syndrome.
    The Cochrane database of systematic reviews, 2012, Feb-15, Issue:2

    Topics: Abortion, Spontaneous; Administration, Oral; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted

2012
Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:2

    Topics: Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Evidence-Based Medicine; Female; Fertility Agents, Female; Gene Expression Regulation; Humans; Ovarian Hyperstimulation Syndrome; Ovary; Phosphorylation; Protein Processing, Post-Translational; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2013

Trials

16 trial(s) available for cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous

ArticleYear
Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: a randomised controlled study.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2022, Volume: 42, Issue:1

    Topics: Adult; Cabergoline; Calcium Gluconate; Female; Fertilization in Vitro; Humans; Incidence; Infusions, Intravenous; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Prospective Studies; Single-Blind Method; Treatment Outcome

2022
Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Journal of gynecology obstetrics and human reproduction, 2017, Volume: 46, Issue:1

    Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Prospective Studies; Severity of Illness Index; Sperm Injections, Intracytoplasmic; Vascular Endothelial Growth Factor A

2017
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2018, Volume: 140, Issue:2

    Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Sperm Injections, Intracytoplasmic

2018
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2018, Volume: 34, Issue:7

    Topics: Adult; Cabergoline; Chemoprevention; Clomiphene; Drug Resistance; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gynecologic Surgical Procedures; Hormone Antagonists; Humans; Infertility, Female; Laparoscopy; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Secondary Prevention; Treatment Failure

2018
Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol.
    Reproductive biology, 2019, Volume: 19, Issue:2

    Topics: Adult; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Sperm Injections, Intracytoplasmic; Young Adult

2019
Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial.
    Reproductive biomedicine online, 2013, Volume: 26, Issue:6

    Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Treatment Outcome

2013
The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:8

    Topics: Adult; Anti-Mullerian Hormone; Cabergoline; Cellular Microenvironment; Cohort Studies; Ergolines; Female; Fertilization in Vitro; Follicular Fluid; Hepatocyte Growth Factor; Humans; Inhibins; Insulin-Like Growth Factor I; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Risk Factors; Young Adult

2013
Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
    European journal of obstetrics, gynecology, and reproductive biology, 2013, Volume: 170, Issue:2

    Topics: Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Hydroxyethyl Starch Derivatives; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Plasma Substitutes; Pregnancy; Pregnancy Rate; Prospective Studies; Secondary Prevention; Triptorelin Pamoate

2013
Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:5

    Topics: Animals; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Ergolines; Eye Proteins; Female; Gonadotropins, Equine; Humans; Letrozole; Nerve Growth Factors; Nitriles; Ovarian Hyperstimulation Syndrome; Ovary; Pregnancy; Prospective Studies; Rats; Rats, Wistar; Serpins; Triazoles; Vascular Endothelial Growth Factor A

2016
GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
    Journal of ovarian research, 2016, May-17, Volume: 9, Issue:1

    Topics: Adult; Antineoplastic Agents; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Incidence; Outcome Assessment, Health Care; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Young Adult

2016
Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.
    Reproductive biomedicine online, 2008, Volume: 17, Issue:6

    Topics: Adult; Albumins; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Fertilization in Vitro; Humans; Oocytes; Ovarian Hyperstimulation Syndrome; Prospective Studies; Risk; Sperm Injections, Intracytoplasmic; Treatment Outcome

2008
Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.
    Journal of assisted reproduction and genetics, 2012, Volume: 29, Issue:3

    Topics: Adult; Cabergoline; Dopamine Agents; Ergolines; Female; Fertilization in Vitro; Humans; Incidence; Infertility; Infusions, Intravenous; Iran; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Risk Factors; Serum Albumin; Serum Albumin, Human; Severity of Illness Index; Sperm Injections, Intracytoplasmic; Young Adult

2012
Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:11

    Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Young Adult

2012
Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.
    European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 165, Issue:2

    Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Sperm Injections, Intracytoplasmic

2012
Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?
    European journal of obstetrics, gynecology, and reproductive biology, 2005, Sep-01, Volume: 122, Issue:1

    Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Treatment Outcome

2005
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:8

    Topics: Adult; Ascites; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Extracellular Space; Female; Fertilization in Vitro; Granulosa Cells; Hematocrit; Hemoglobins; Humans; Image Processing, Computer-Assisted; Luteal Cells; Magnetic Resonance Imaging; Ovarian Hyperstimulation Syndrome; Ovary; Pregnancy; Prospective Studies; Receptors, Dopamine D2; Regional Blood Flow; Reverse Transcriptase Polymerase Chain Reaction

2007

Other Studies

34 other study(ies) available for cabergoline and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous

ArticleYear
Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome.
    European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:4

    Topics: Cabergoline; Calcium Gluconate; Dopamine Agonists; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate

2022
Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin.
    Archives of gynecology and obstetrics, 2022, Volume: 306, Issue:5

    Topics: Cabergoline; Chorionic Gonadotropin; Electrolytes; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Retrospective Studies; Vascular Endothelial Growth Factor A

2022
Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2022, Volume: 38, Issue:12

    Topics: Animals; Cabergoline; Dopamine Agonists; Endothelial Cells; Female; Humans; Ondansetron; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Serotonin; Vascular Endothelial Growth Factor A

2022
Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2023, Volume: 39, Issue:1

    Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2023
Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.
    Revista da Associacao Medica Brasileira (1992), 2023, Volume: 69, Issue:11

    Topics: Animals; Body Weight; Cabergoline; Female; Horses; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A

2023
Late-onset ovarian hyperstimulation syndrome developing during ovarian stimulation in an ectopic pregnancy: a case report.
    Journal of medical case reports, 2020, Jul-20, Volume: 14, Issue:1

    Topics: Adult; Cabergoline; Chorionic Gonadotropin; Estradiol; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy, Ectopic

2020
Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Archives of gynecology and obstetrics, 2021, Volume: 303, Issue:4

    Topics: Animals; Cabergoline; Disease Models, Animal; Female; Ovarian Hyperstimulation Syndrome; Oxytocics; Oxytocin; Rats; Rats, Sprague-Dawley; Rats, Wistar; Vascular Endothelial Growth Factor A

2021
Combining several interventions to reduce the incidence of OHSS: A prospective cohort study.
    European journal of obstetrics, gynecology, and reproductive biology, 2017, Volume: 212

    Topics: Adult; Aspirin; Cabergoline; Chorionic Gonadotropin; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Reproductive Control Agents; Severity of Illness Index

2017
Lifesaving dose increment of cabergoline in life-threatening spontaneous ovarian hyperstimulation syndrome resistant to all interventions.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2019, Volume: 35, Issue:4

    Topics: Adult; Cabergoline; Dopamine Agonists; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Complications

2019
What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2019, Volume: 39, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Cabergoline; Chorionic Gonadotropin; Clarithromycin; Disease Models, Animal; Dopamine Agonists; Estradiol; Female; Gonadotropins, Equine; Interleukin-10; Interleukin-1beta; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2019
Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?
    Drug design, development and therapy, 2019, Volume: 13

    Topics: Animals; Cabergoline; Celecoxib; Cyclooxygenase Inhibitors; Female; Injections, Subcutaneous; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar

2019
Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome.
    Reproductive biomedicine online, 2019, Volume: 39, Issue:3

    Topics: Adult; Buserelin; Cabergoline; Dopamine Agonists; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Retrospective Studies

2019
Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
    Journal of assisted reproduction and genetics, 2013, Volume: 30, Issue:6

    Topics: Adult; Cabergoline; Cryopreservation; Embryo Transfer; Ergolines; Estradiol; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Retrospective Studies; Sperm Injections, Intracytoplasmic

2013
Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
    Archives of gynecology and obstetrics, 2013, Volume: 288, Issue:5

    Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone; Hormones; Humans; Infertility, Female; Leuprolide; Longitudinal Studies; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Retrospective Studies; Young Adult

2013
Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2013, Volume: 29, Issue:9

    Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cabergoline; Cell Count; Disease Models, Animal; Drug Evaluation, Preclinical; Ergolines; Female; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovum; Rats; Rats, Wistar

2013
[Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
    Akusherstvo i ginekologiia, 2014, Volume: 53, Issue:5

    Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy

2014
Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015, Volume: 31, Issue:5

    Topics: Acetates; Animals; Ascitic Fluid; Body Weight; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Cyclopropanes; Dopamine Agonists; Ergolines; Female; Gonadotropins, Equine; Horses; Humans; Immunohistochemistry; Leukotriene Antagonists; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Quinolines; Rats; Rats, Wistar; Reproductive Control Agents; Sulfides; Vascular Endothelial Growth Factor A

2015
Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015, Volume: 31, Issue:12

    Topics: Animals; Antibodies, Monoclonal, Humanized; Cabergoline; Ergolines; Estrogens; Female; Gonadotropin-Releasing Hormone; Interleukin-6; Ovarian Hyperstimulation Syndrome; Ovary; Progesterone; Ranibizumab; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A

2015
Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
    Ginekologia polska, 2015, Volume: 86, Issue:8

    Topics: Acetates; Animals; Cabergoline; Chorionic Gonadotropin; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Quinolines; Random Allocation; Rats; Rats, Wistar; Sulfides

2015
Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:8

    Topics: Animals; Antioxidants; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Ovarian Hyperstimulation Syndrome; Ovary; Random Allocation; Rats; Rats, Wistar; Resveratrol; Stilbenes

2016
An update on the prevention of ovarian hyperstimulation syndrome.
    Women's health (London, England), 2016, Volume: 12, Issue:5

    Topics: Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Kisspeptins; Leuprolide; Luteinizing Hormone; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Recombinant Proteins; Reproductive Control Agents; Risk Assessment

2016
High dose cabergoline in management of ovarian hyperstimulation syndrome.
    Fertility and sterility, 2009, Volume: 92, Issue:3

    Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Severity of Illness Index; Treatment Outcome

2009
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.
    Fertility and sterility, 2009, Volume: 92, Issue:3

    Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Treatment Outcome

2009
Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2010, Volume: 108, Issue:2

    Topics: Adult; Antineoplastic Agents; Cabergoline; Ergolines; Estradiol; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Treatment Failure

2010
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
    Acta obstetricia et gynecologica Scandinavica, 2010, Volume: 89, Issue:5

    Topics: Analysis of Variance; Animals; Biopsy, Needle; Body Weight; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Immunohistochemistry; Injections, Intramuscular; Meloxicam; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy; Pregnancy, Animal; Probability; Random Allocation; Rats; Rats, Wistar; Thiazines; Thiazoles; Vascular Endothelial Growth Factor A

2010
[Spontaneous ovarian hyperstimulation syndrome in a pregnancy with hypothyroidism].
    Gynecologie, obstetrique & fertilite, 2011, Volume: 39, Issue:3

    Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Cabergoline; Chorionic Gonadotropin; Ergolines; Female; Fibrinolytic Agents; Follicle Stimulating Hormone; Gestational Age; Graves Disease; Humans; Hypothyroidism; Luteinizing Hormone; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Complications; Thyroidectomy; Thyrotropin

2011
[Clinical utility of cabergoline in ovarian hyperstimulation syndrome].
    Revista espanola de anestesiologia y reanimacion, 2011, Volume: 58, Issue:2

    Topics: Adult; Cabergoline; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome

2011
Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:8

    Topics: Adult; Cabergoline; Cells, Cultured; Dopamine; Dopamine Agonists; Ergolines; Female; Granulosa Cells; Humans; Luteal Cells; Neovascularization, Physiologic; Oocytes; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Receptors, Dopamine D2; Risk Factors; Signal Transduction; Tissue Banks; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2011
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Endocrinology, 2006, Volume: 147, Issue:11

    Topics: Animals; Cabergoline; Capillary Permeability; Corpus Luteum; Disease Models, Animal; Dopamine Agonists; Ergolines; Female; Neovascularization, Physiologic; Ovarian Hyperstimulation Syndrome; Phosphorylation; Rats; Rats, Wistar; Receptors, Dopamine D2; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2006
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
    Fertility and sterility, 2006, Volume: 86, Issue:3

    Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms

2006
An important new adaption of a specific drug?
    Fertility and sterility, 2007, Volume: 88, Issue:2

    Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A

2007
Editorial: Preventing ovarian hyperstimulation syndrome.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:8

    Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A

2007
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
    Human reproduction (Oxford, England), 2007, Volume: 22, Issue:12

    Topics: Adult; Cabergoline; Dopamine Agonists; Embryo Implantation; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pilot Projects; Pregnancy; Pregnancy Rate; Reproductive Techniques, Assisted; Retrospective Studies

2007
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
    Human reproduction (Oxford, England), 2001, Volume: 16, Issue:11

    Topics: Adult; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Infertility, Female; Ovarian Follicle; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Recombinant Proteins; Time Factors; Ultrasonography

2001